These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 22960765)

  • 1. Inosine monophosphate dehydrogenase polymorphisms and renal allograft outcome.
    Shah S; Harwood SM; Döhler B; Opelz G; Yaqoob MM
    Transplantation; 2012 Sep; 94(5):486-91. PubMed ID: 22960765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of IMPDH1 gene polymorphisms with subclinical acute rejection and mycophenolic acid exposure parameters on day 28 after renal transplantation.
    Kagaya H; Miura M; Saito M; Habuchi T; Satoh S
    Basic Clin Pharmacol Toxicol; 2010 Aug; 107(2):631-6. PubMed ID: 20136638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients.
    Wang J; Yang JW; Zeevi A; Webber SA; Girnita DM; Selby R; Fu J; Shah T; Pravica V; Hutchinson IV; Burckart GJ
    Clin Pharmacol Ther; 2008 May; 83(5):711-7. PubMed ID: 17851563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil.
    Gensburger O; Van Schaik RH; Picard N; Le Meur Y; Rousseau A; Woillard JB; Van Gelder T; Marquet P
    Pharmacogenet Genomics; 2010 Sep; 20(9):537-43. PubMed ID: 20679962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism.
    Sombogaard F; van Schaik RH; Mathot RA; Budde K; van der Werf M; Vulto AG; Weimar W; Glander P; Essioux L; van Gelder T
    Pharmacogenet Genomics; 2009 Aug; 19(8):626-34. PubMed ID: 19617864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of inosine monophosphate dehydrogenase type I and type II after mycophenolate mofetil treatment: a 2-year follow-up in kidney transplantation.
    Sanquer S; Maison P; Tomkiewicz C; Macquin-Mavier I; Legendre C; Barouki R; Lang P
    Clin Pharmacol Ther; 2008 Feb; 83(2):328-35. PubMed ID: 17713475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphisms in IMPDH2, UGT2B7, and CES2 genes influence the risk of graft rejection in kidney transplant recipients taking mycophenolate mofetil.
    Cilião HL; Camargo-Godoy RBO; Souza MF; Zanuto A; Delfino VDA; Cólus IMS
    Mutat Res Genet Toxicol Environ Mutagen; 2018 Dec; 836(Pt B):97-102. PubMed ID: 30442353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malnutrition Risk in Kidney Recipients Treated With Mycophenolate Mofetil Is Associated With IMPDH1 rs2278294 Polymorphism.
    Pazik J; Lewandowski Z; Nowacka Cieciura E; Ołdak M; Podgórska M; Sadowska A; Dęborska Materkowska D; Durlik M
    Transplant Proc; 2018; 50(6):1794-1797. PubMed ID: 30056902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients.
    Glander P; Hambach P; Braun KP; Fritsche L; Waiser J; Mai I; Neumayer HH; Budde K
    Int J Clin Pharmacol Ther; 2003 Oct; 41(10):470-6. PubMed ID: 14703953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients.
    Vannozzi F; Filipponi F; Di Paolo A; Danesi R; Urbani L; Bocci G; Catalano G; De Simone P; Mosca F; Del Tacca M
    Transplant Proc; 2004 Nov; 36(9):2787-90. PubMed ID: 15621150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic association of FOXP3 gene polymorphisms with allograft rejection in renal transplant patients.
    Qiu XY; Jiao Z; Zhang M; Chen JP; Shi XJ; Zhong MK
    Nephrology (Carlton); 2012 May; 17(4):423-30. PubMed ID: 22239151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy.
    Chiarelli LR; Molinaro M; Libetta C; Tinelli C; Cosmai L; Valentini G; Dal Canton A; Regazzi M
    Br J Clin Pharmacol; 2010 Jan; 69(1):38-50. PubMed ID: 20078611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation.
    Glander P; Hambach P; Braun KP; Fritsche L; Giessing M; Mai I; Einecke G; Waiser J; Neumayer HH; Budde K
    Am J Transplant; 2004 Dec; 4(12):2045-51. PubMed ID: 15575908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients.
    Ohmann EL; Burckart GJ; Brooks MM; Chen Y; Pravica V; Girnita DM; Zeevi A; Webber SA
    J Heart Lung Transplant; 2010 May; 29(5):509-16. PubMed ID: 20061166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphocyte counts in kidney allograft recipients are associated with IMPDH2 3757T>C gene polymorphism.
    Pazik J; Ołdak M; Podgórska M; Lewandowski Z; Sitarek E; Płoski R; Szmidt J; Chmura A; Durlik M; Malejczyk J
    Transplant Proc; 2011 Oct; 43(8):2943-5. PubMed ID: 21996196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group.
    Transplantation; 1999 Aug; 68(3):391-6. PubMed ID: 10459543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment.
    Vethe NT; Mandla R; Line PD; Midtvedt K; Hartmann A; Bergan S
    Scand J Clin Lab Invest; 2006; 66(1):31-44. PubMed ID: 16464785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inosine 5'-Monophosphate Dehydrogenase Activity for the Longitudinal Monitoring of Mycophenolic Acid Treatment in Kidney Allograft Recipients.
    Glander P; Waiser J; Hambach P; Bachmann F; Budde K; Eckardt KU; Friedersdorff F; Gaedeke J; Kron S; Lorkowski C; Mai M; Neumayer HH; Peters R; Rudolph B; Schmidt D; Wu K; Liefeldt L
    Transplantation; 2021 Apr; 105(4):916-927. PubMed ID: 32496356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of mycophenolate mofetil and azathioprine dose on renal allograft outcome in the United kingdom.
    Shah S; Collett D; Johnson R; Raftery M; Rudge C; Yaqoob MM
    Transplantation; 2008 Oct; 86(8):1035-42. PubMed ID: 18946340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update.
    Staatz CE; Tett SE
    Arch Toxicol; 2014 Jul; 88(7):1351-89. PubMed ID: 24792322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.